{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:22:38Z","timestamp":1788992558006,"version":"build-2803163510"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"suppl_6","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis and Pfizer"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie and Janssen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1093\/rheumatology\/key152","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T19:10:19Z","timestamp":1526065819000},"page":"vi23-vi28","source":"Crossref","is-referenced-by-count":31,"title":["Therapies in ankylosing spondylitis\u2014from clinical trials to clinical practice"],"prefix":"10.1093","volume":"57","author":[{"given":"Hasan","family":"Tahir","sequence":"first","affiliation":[{"name":"Rheumatology, Whipps Cross University Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"key\n\t\t\t\t2018112010224929200_key152-B1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/ard.2007.074724","article-title":"Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions","volume":"67","author":"van der Heijde","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B5","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B6","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B7","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.2011.154799","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B12","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/annrheumdis-2016-eular.5795","article-title":"SAT0380 NSAIDs modify the effect of tumor necrosis factor inhibitors on new bone formation in ankylosing spondylitis","volume":"75(Suppl 2)","author":"Gensler","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B22","year":"2017"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng.513","article-title":"Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci","volume":"42","author":"Reveille","year":"2010","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2013.07.016","article-title":"Inflammatory pathways in spondyloarthritis","volume":"57","author":"Hreggvidsdottir","year":"2014","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B26","doi-asserted-by":"crossref","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PloS One"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B27","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molimm.2013.06.010","article-title":"The critical role of interleukin-23 in spondyloarthropathy","volume":"57","author":"Sherlock","year":"2014","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B29","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.37937","article-title":"In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis","volume":"65","author":"Appel","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B30","first-page":"S1083","article-title":"Ustekinumab in patient with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, PSUMMIT I study","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B32","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B34","year":"2017"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B35","year":"2017"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1517\/13543784.2012.690029","article-title":"JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy","volume":"21","author":"Vaddi","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B37"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B38","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomized, placebo-controlled, dose-ranging study","volume":"76","author":"van Der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0002-9440(10)62961-6","article-title":"Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1","volume":"167","author":"Koenders","year":"2005","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B40","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B41","first-page":"S972","article-title":"Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging","volume":"63","author":"Baraliakos","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B42","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B43","first-page":"281","article-title":"THU0233 Secukinumab reduces sacroiliac joint and spinal inflammation in patients with ankylosing spondylitis: MRI data from a phase 3 randomized, double-blind, placebo-controlled study (MEASURE 1)","volume":"74 (Suppl 2)","author":"Baraliakos","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B44","article-title":"Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab","volume":"67","author":"Baraliakos","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B45","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled trial","volume":"67(Supp 10)","author":"Baeten","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B46","first-page":"108","article-title":"Secukinumab reduces signs and symptoms of active ankylosing spondylitis: results from a 16-week, randomized, placebo-controlled phase 3 trial","volume":"22","author":"Kivitz","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B47","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: cLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B50","year":"2017"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B51","year":"2017"},{"key":"key\n\t\t\t\t2018112010224929200_key152-B52","year":"2017"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/suppl_6\/vi23\/26660375\/key152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:07:49Z","timestamp":1751634469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/suppl_6\/vi23\/5184854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":52,"journal-issue":{"issue":"suppl_6","published-online":{"date-parts":[[2018,11,16]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key152","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,11,1]]}}}